

Malaria vaccines targeting Pfs25 antigen in parasite mosquito stages to block transmission

Abstract.

Transmission of malaria involves *Anopheles* mosquitoes as the vectors of the *Plasmodium* parasite. The malaria eradication program includes the distribution of insecticide-treated bednets. However, the *Anopheles* mosquitoes have developed insecticide resistance hence it is necessary to find other modalities to eradicate the disease. Because the parasites undergo several stages in the mosquito midgut before developing into infective stages that migrate to the salivary gland, it is of interest to target the mosquito stages in vaccination to block the transmission. Human vaccination with the antigen of the mosquito stages may induce the production of specific antibodies against the stages that might be transferred into the mosquito during blood meal, binding with the antigen of the mosquito stages in the midgut and subsequently disrupting the development of the parasite. Such a vaccine is called a transmission-blocking vaccine (TBV). An effective TBV should induce a high titer of antibody for a long time. One of the leading antigens is Pfs25. Here we review the update of TBV development targeting Pfs25, advances in the transmission-blocking assay, and challenges in the development of TBVs.

Keywords: TBV, Pfs25, malaria, *Plasmodium*, mosquito stages, TBA

1. Introduction

Malaria eradication has been a long-term goal with many challenges to face. Several strategies have been employed such as deployment of artemisinin-based therapy, distribution of insecticide-treated bednets, and vector control measures. However, there has been no significant change in the number of cases and deaths in the last few years. Based on the latest WHO Malaria Report 2023, the global estimated number of cases in 2022 was 249 million with estimated deaths of 608000 [1].

Therefore, a novel modality for transmission-blocking such as vaccination should be developed. Since the malaria parasite life cycle involves two hosts, the humans, and mosquitoes, vaccination may target the parasite stages either in humans or in the mosquitoes. Targeting the mosquito stages may inhibit the growth of the parasite in the mosquitoes which eventually blocks the transmission into humans. Such vaccines are called transmission-blocking vaccine (TBV) [2, 35-38].

In this review, we will discuss the update on the development of the TBVs, advances in the transmission-blocking assay, and challenges in the development of the TBVs.

2. Transmission-Blocking Vaccine (TBV) Targets Mosquito Stages

The life cycle of *Plasmodium spp* in mosquitoes starts when a female *Anopheles* mosquito feeds from an infected human. During the blood meal, *Plasmodium* gametocytes are taken up by the mosquito. In the mosquito midgut, the macrogametocytes and microgametocytes mature into gametes which will fuse to form the ookinete. The ookinete migrates to the external surface of the stomach and matures into an oocyst that contains up to 10,000 sporozoites in a few days (Fig 1). The sporozoites are then released to the circulation when an oocyst ruptures, reaching the salivary gland where they are ready to be injected into the human when the mosquito takes the next blood meal [3,4].



Fig 1. The development of malaria parasites in the mosquitoes. The gametocytes are taken up from an infected human during blood meal which develop into gametes in mosquito midgut. The final stages are sporozoites that are injected into human skin during another blood meal.

The surface proteins of the mosquito stages have been targeted for the development of TBVs, such as Pfs25, Pfs28, Pfs48/45 and Pfs230 [2]. When these antigens are injected into the human body, they induce antibodies in the blood that will be ingested by a mosquito during a blood meal and subsequently disrupt the development of the parasite. Inducing antibodies against the stages in the mosquitoes would be more advantageous than antibodies against the erythrocytic stages because the number of parasites in the midgut is far lower than the number of parasites in human circulation. Thus, the higher the titer of the induced antibody, the more efficacious the TBV is to inhibit the formation of the mosquito stages [5].

Among all vaccine targets, Pfs25 has been the leading candidate showing promising results from several animal studies in different laboratories and has entered clinical trials [6,7,8]. Pfs25 is a cysteine-rich 217-amino acid composed of four tandem epidermal growth factor (EGF)-like domains and encoded by a 0.65-kb gene. Pfs25 is predicted to be a 25-kDa glycosylphosphatidylinositol (GPI)-anchored protein belonging to a 13-member P25 family of proteins [9,10]. The protein is involved in ookinete formation, survival in the mosquito midgut, and a possible role in parasite traversal of the mid-gut epithelium [11,12]. Based on structural analyses of the *P. vivax* ortholog Pvs25, the Pfs25 molecule is thought to be triangular and flat, and extensively expressed on the ookinete surface, forming a protective interlocking sheet [10,13,14]. Below we discuss several Pfs25-targeting vaccine candidates reported recently.




Fig 2. Superposition of site 1a antibody–Pfs25 co-complex crystal structures. Pfs25 is shown as a cartoon and colored according to the EGF-like domain [10].

2.1 Pfs25-EPA

This vaccine consists of Pfs25H, a recombinant *Pichia pastoris* expressed Pfs25 protein with a 6-histidine fusion tag adjuvanted on Alhydrogel (Table 1) [15]. The antigen was conjugated to EPA, a recombinant, detoxified ExoProtein A from *Pseudomonas aeruginosa* to enhance the vaccine immunogenicity. The Pfs25-EPA has entered a phase 1 clinical trial but despite the ability to induce antibody titer against Pfs25 with minimal adverse events, the antibody titer reduced to near baseline after one year [16]. A study by Sara A. Healy in 2021 compared the effectivity of pfs25-EPA and Pfs230D1-EPA in mice and humans. The result identified that Pfs25-EPA and Pfs230D1-EPA induced similar serum functional activity in mice, but Pfs230D1-EPA induced significantly greater activity in rhesus monkeys [17]. **Pre-clinical**

evaluations of Pfs25-EPA and Pfs230D1-EPA nanoparticles with GSK platforms were stable after a series of assessments and induced superior antibody titers and functional activity in CD-1 mice, compared to Alhydrogel formulations of the same antigens [18]. In US adults, 2 vaccine doses induced complement-dependent activity in 4 of 5 Pfs230D1-EPA recipients but no significant activity in 5 Pfs25-EPA recipients, and combination with Pfs25-EPA did not increase activity more than Pfs230D1-EPA alone (Table 1). Studies using mRNA constructs of Pfs25 and Pfs230D1 incorporating various signal peptides, GPI anchors, and Trans Membrane (TM) domains showed that Pfs25 mRNA constructs with a GPI anchor or TM domain resulted in high cell surface antigen expression and produced a strong immune response in mice [19,20].

Table 1. Phase 1 clinical trials of Pfs25-based vaccines

Author (year)	Vaccine	Number of study subjects; ages (y.o)	Results
Talaat KR, et al. (2016) [16].	Pfs25-EPA / Alhydrogel	30; 18–50	The vaccine was well tolerated 9/11 subjects develop TRA 50%
Sara A. Healy et al (2020) [17].	Pfs25-EPA/Alhydrogel	5; 18–50	The vaccine was well tolerated 0 of 5 individuals had TRA greater than 50%
J.A. Chichester et al.(2018) [21].	Pfs25 VLP-FhCMB /Alhydrogel	44; 18-50	Acceptable safety and tolerability profile TRA was significant after the 3 rd dose in 2/8 subjects (80% and 77%)
de Graaf et al. (2021) [22,23].	ChAd63-Pfs25-IMX313/ MVA-Pfs25-IMX313 prime-boost	26; 18-50	Both vaccines were well tolerated and demonstrated a favorable safety profile Median Transmission Reduction Activity (TRA) was 25.3%
Sagara et al. (2023) [24].	Pfs25-EPA/Alhydrogel-Pfs230D1-EPA/Alhydrogel.	471; 18-50	Pfs230D1 but not Pfs25 vaccine induces durable serum functional activity in Malian adults

2.2 Pfs25 VLP-FhCMB

Pfs25 VLP-FhCMB is a chimeric non-enveloped virus-like particle (VLP) comprising Pfs25 which is fused to the *Alfalfa* mosaic virus coat protein and manufactured in *Nicotiana benthamiana* plants. It has also entered a clinical trial, but the result was unsatisfactory due to the poor efficacy despite the ability to induce antibody titer against Pfs25. It was reported that the transmission-reducing activity (TRA) was less than 80% in the majority of study subjects (Table 1) [21].

2.3 ChAd63-Pfs25-IMX313/MVA-Pfs25-IMX313

This vaccine is a fusion of Pfs25 to IMX313, an oligomerization technology to produce a homogenous, self-assembling oligomer of Pfs25 resembling a nanoparticle. The particles are then expressed in the viral vectors, chimpanzee adenovirus serotype 63 (ChAd63) and MVA [25]. A first-phase clinical trial using this vaccine has already been done by Hans de Graaf et al [22] between 2019 and 2021. The result shows that the vaccines were immunogenic and induced both antibody and T-cell responses against Pfs25. However, significant TRA was not observed in most volunteers by standard membrane feeding assay, suggesting the need for an alternative vaccine formulation (Table 1) [19]. Another study by Marija Zaric [26] reveals the reason behind this result. They found that the key determinant for the poor anti-Pfs25 antibody

formation in humans was the lack of CD4⁺ T cell recognition of Pfs25-IMX313 derived peptide epitopes. This is supported by correlations established between the ratio of proliferated antigen-specific CD4⁺/Tfh-like T cells, CXCL13 sera levels, and the corresponding numbers of circulating Pfs25-specific memory B cells, that consequently reflected on antigen-specific IgG sera levels [26].

2.4 Ad5-Pfs25

The Ad5-Pfs25 is a Pfs25 encoding gene delivered by an adenovirus type 5 vector. In an animal study, this vaccine was used as a prime injection of a boost of Ad5 viral particles displaying only the Pfs25 epitope targeted by the specific antibodies against Pfs25 4B7 and 1D2 (Pfs25 aa 122–134) [27]. Another animal study used the Ad5-Pfs25 in a heterologous prime-boost with a Modified Vaccinia Ankara (MVA)-vectored Pfs25, resulting in a 96% reduction in the oocyst intensity [28]. However, there is no report yet about whether this vaccine has entered a clinical trial.

3. Advances in transmission-blocking assay

The efficacy of a TBV is evaluated using a method known as transmission-blocking assay (TBA). To date, there are two kinds of TBA; standard membrane feeding assay (SMFA) and direct feeding assay (DFA). The oocyst numbers and prevalence are counted and compared between the immunized and control groups for the inhibition calculation. The efficacy could be presented in two outreads; transmission-blocking activity (TBA) and transmission-reducing activity (TRA) [6].

3.1 SMFA and DFA

In an SMFA, after immunization, sera are collected and then mixed with the mosquito blood meal in a membrane feeder containing *P. falciparum* strain NF54 that has been induced for gametocytogenesis. After taking blood, mosquitoes are maintained for around 10 days and then their midgut is dissected for oocyst examination for their intensity and prevalence (Fig 3). This method is used more commonly in transmission-blocking assay, including in human trials.




Fig 3. Standard Membrane Feeding Assay.

After immunization (prime and boost), sera are collected and mixed with the *P. falciparum* culture for membrane feeding of the mosquitoes. The development of oocysts in the mosquito midgut is evaluated after 10-12 days

In a DFA, the mosquitoes directly feed from the immunized mice instead of feeding from a membrane. The immunized mice are infected with the transgenic parasite *P. berghei* containing the Pfs25 gene (*PbPfs25DR3*) before blood-feeding (Fig 4) [28]. It has been suggested that this assay is twice as effective as SMFA, but it requires a high infection rate if applied in clinical trials to assess vaccine effectiveness in blocking transmission [24,29].




Fig 4. Direct Feeding Assay.

After immunization (prime and boost), mice are infected with the *PbPfs25DR3*. Mosquitoes are allowed to take blood directly from the mice and the development of oocysts in the midgut is evaluated after 10-12 days

3.2 TBA and TRA

The Transmission-reducing activity (TRA) indicates the percent inhibition of mean oocyst intensity which is calculated using the formula: $100 \times [1 - (\text{mean number of oocysts in the test group} / \text{mean number of oocysts in the control groups})]$. Whereas, transmission-blocking activity (TBA) indicates the % inhibition of oocyst prevalence which is evaluated as: $100 \times [1 - (\text{proportion of mosquitoes with any oocysts in the test group} / \text{proportion of mosquitoes with any oocysts in the control groups})]$ [30]. It was reported that the variability of inter-laboratory results might be reduced by reporting the TBV efficacy in TRA [31].

4. Challenges in the development of TBV

Since the Pfs25 are expressed in the mosquito stages, natural infection cannot boost the immune response against this antigen. Thus, the antibody titer may wane over time. To overcome this problem, an effective TBV should be able to induce a long-lasting immune response, particularly antibody induction. Induction of long-term antibody response has been reported previously in a study using Ad5-Pfs25 prime followed by an Adeno-associated virus serotype 1 (AAV1)-vectored Pfs25 boost [32].

Another challenge this vaccination faces is the ethical issue of not giving protection from malaria [33]. It has been highlighted that vaccination should give protection to the people who get vaccinated with TBV, in addition to inhibiting the parasite transmission. This was addressed by the study on co-administration of vaccines targeting PfCSP and those targeting Pfs25 [7,20]. In a study on the potential mixing of Pfs25-IMX313 with RTS,S/AS01 in one formulation, it was reported that the mixture was able to induce immune responses against the pre-erythrocytic stage and the mosquito stage hence it may be effective for both protection and transmission-blocking [7]. A similar result was achieved by a co-administration of mRNA-based vaccines targeting either PfCSP or Pfs25 [20].

A more efficient approach was to produce a multi-stage vaccine, combining the sequence of antigens of both stages in one construct. In an animal study using DFA, a heterologous prime-boost using Ad5-AAV1 delivering the multistage PfCSP-Pfs25 antigen induced long-term antibody titer against both antigens and protected mice from developing blood stage parasites [33]. In addition, the vaccine achieved a high efficacy of 99% TRA even after almost 1 year. If such efficacy can be reached in humans, we may achieve the goal of eradicating malaria.

5. Conclusion

An effective vaccine targeting the antigen of the mosquito stages of the malaria parasite might be a powerful alternative modality for malaria control. More intensive studies are needed to explore the potency of Pfs25 as the leading candidate to be an effective TBV.

Conflict of Interest

The authors declare no conflict of interest

Disclaimer (Artificial intelligence)

Authors hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during the writing or editing of manuscripts.

References

1. WHO. (2023, 30 November 2023). World malaria report 2023, Retrieved 18 June 2024, from <https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2023>
2. Duffy, P. E., and D. C. Kaslow. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. *Infect Imm.* 1997;65(3): 1109.
3. Institute of Medicine (US) Committee for the Study on Malaria Prevention and Control. 1991. 6, Parasite Biology. Malaria: Obstacles and Opportunities. M. V. Oaks SC Jr, Pearson GW, et al. Washington DC, National Academies Press
4. Aly, A. S. I., A. M. Vaughan and S. H. I. Kappe. Malaria parasite development in the mosquito and infection of the mammalian host. *Ann rev microbiol.* 2009;63: 195-221.
5. Miura, K., D. B. Keister, O. V. Muratova, J. Sattabongkot, C. A. Long, and A. Saul. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. *Malar J.* 2007;6(1): 107.
6. Miura, K., E. Takashima, B. Deng, G. Tullo, A. Diouf, S. E. Moretz, D. Nikolaeva, M. Diakite, R. M. Fairhurst, M. P. Fay, C. A. Long, and T. Tsuboi. Functional comparison of *Plasmodium falciparum* transmission-blocking vaccine candidates by the standard membrane-feeding assay. *Infect Imm.* 2013;81(12): 4377.
7. Brod, F., K. Miura, I. Taylor, Y. Li, A. Marini, A. M. Salman, A. J. Spencer, C. A. Long, and S. Biswas. Combination of rts,s and pfs25-imx313 induces a functional antibody response against malaria infection and transmission in mice. *Front Imm.* 2013;9: 2780.
8. Kaslow DC. Efforts to Develop Pfs25 Vaccines. *Am J Trop Med Hyg.* 2022;tpmd211326.
9. Kaslow DC, Quakyi IA, Syin C, Raum MG, Keister DB, Coligan JE, McCutchan TF, Miller LH. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. *Nature.* 1988;333(6168):74-6.
10. Scally SW, McLeod B, Bosch A, Miura K, Liang Q, Carroll S, Reponen S, Nguyen N, Giladi E, Rämisch S, Yusibov V, Bradley A, Lemiale F, Schief WR, Emerling D, Kellam P, King CR, Julien JP. Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25. *Nat Commun.* 2017;8(1):1568.
11. Sauerwein, R. W., and T. Bousema. Transmission blocking malaria vaccines: Assays and candidates in clinical development. *Vaccine.* 2015;33(52): 7476-7482.
12. Baton LA, Ranford-Cartwright LC. Do malaria ookinete surface proteins P25 and P28 mediate parasite entry into mosquito midgut epithelial cells? *Malar J.* 2005;4:15.
13. Saxena AK, Singh K, Su HP, Klein MM, Stowers AW, Saul AJ, Long CA, Garboczi DN. The essential mosquito-stage P25 and P28 proteins from *Plasmodium* form tile-like triangular prisms. *Nat Struct Mol Biol.* 2006;13(1):90-1.
14. Stowers AW, Keister DB, Muratova O, Kaslow DC. A region of *Plasmodium falciparum* antigen Pfs25 that is the target of highly potent transmission-blocking antibodies. *Infect Immun.* 2000;68:5530-8.
15. Zhu, D., Y. Wu, H. McClellan, W. Dai, K. Rausch, D. Jones, J. Aebig, E. Barnafo, B. Butler, L. Lambert, D. L. Narum and P. E. Duffy. Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®. *Vaccine.* 2017;35(24): 3232-3238.

16. Talaat, K. R., R. D. Ellis, J. Hurd, A. Hentrich, E. Gabriel, N. A. Hynes, K. M. Rausch, D. Zhu, O. Muratova, R. Herrera, C. Anderson, D. Jones, J. Aebig, S. Brockley, N. J. MacDonald, X. Wang, M. P. Fay, S. A. Healy, A. P. Durbin, D. L. Narum, Y. Wu and P. E. Duffy. Safety and immunogenicity of pfs25-epa/alhydrogel®, a transmission blocking vaccine against *Plasmodium falciparum*: an open label study in malaria naïve adults. PLoS One. 2016;11(10): e0163144.
17. Healy SA, Anderson C, Swihart BJ, Mwakingwe A, Gabriel EE, Decederfelt H, Hobbs CV, Rausch KM, Zhu D, Muratova O, Herrera R, Scaria PV, MacDonald NJ, Lambert LE, Zaidi I, Coelho CH, Renn JP, Wu Y, Narum DL, Duffy PE. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice. J Clin Invest. 2021 Apr 1;131(7):e146221.
18. Rausch KM, Barnafo EK, Lambert LE, Muratova O, Gorres JP, Anderson C, Narum DL, Wu Y, Morrison RD, Zaidi I, Duffy PE. Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission. iScience. 2023;26(7):107192.
19. Scaria PV, Roth N, Schwendt K, Muratova OV, Alani N, Lambert LE, Barnafo EK, Rowe CG, Zaidi IU, Rausch KM, Narum DL, Petsch B, Duffy PE. mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response. NPJ Vaccines. 2024;9(1):9.
20. Hayashi CTH, Cao Y, Clark LC, Tripathi AK, Zavala F, Dwivedi G, Knox J, Alameh MG, Lin PJC, Tam YK, Weissman D, Kumar N. mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum. NPJ Vaccines. 2022 Dec 1;7(1):155. doi: 10.1038/s41541-022-00577-8. Erratum in: NPJ Vaccines. 2023;8(1):115.
21. Chichester JA, Green BJ, Jones RM, Shoji Y, Miura K, Long CA, Lee CK, Ockenhouse CF, Morin MJ, Streatfield SJ, Yusibov V. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults. Vaccine. 2018;36(39):5865-5871.
22. de Graaf H, Payne RO, Taylor I, Miura K, Long CA, Elias SC, Zaric M, Minassian AM, Silk SE, Li L, Poulton ID, Baker M, Draper SJ, Gbesemete D, Brendish NJ, Martins F, Marini A, Mekhaieel D, Edwards NJ, Roberts R, Vekemans J, Moyle S, Faust SN, Berrie E, Lawrie AM, Hill F, Hill AVS and Biswas S. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. Frontiers in Immunology. 2021;12:1–13.
23. Mulamba C, Williams C, Kreppel K, Ouedraogo JB, Olotu AI. Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings. Malar J. 2022;21(1):159.
24. Sagara I, Healy SA, Assadou MH, Kone M, Swihart BJ, Kwan JL, Fintzi J, Sissoko K, Kamate B, Samake Y, Guindo MA, Doucoure M, Niaré K, Dolo A, Diarra B, Rausch KM, Narum DL, Jones DS, MacDonald NJ, Zhu D, Gorres JP, Imeru A, Mohan R, Thera I, Zaidi I, Salazar-Mirallas F, Duan J, Neal J, Morrison RD, Muratova O, Sylla D, O'Connell EM, Wu Y, Hume JCC, Coulibaly MB, Anderson CF, Traore SF, Doumbo OK, Duffy PE. Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial. Lancet Infect Dis. 2023;23(11):1266-1279.
25. Li, Y., D. B. Leneghan, K. Miura, D. Nikolaeva, I. J. Brian, M. D. J. Dicks, A. J. Fyfe, S. E. Zakutansky, S. de Cassan, C. A. Long, S. J. Draper, A. V. S. Hill, F. Hill and S. Biswas. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology. Sci rep. 2016;6: 18848-18848.
26. Zaric M, Marini A, Nielsen CM, Gupta G, Mekhaieel D, Pham TP, Elias SC, Taylor IJ, de Graaf H, Payne RO, Li Y, Silk SE, Williams C, Hill AVS, Long CA, Miura K, Biswas S. Poor CD4⁺ T Cell Immunogenicity Limits Humoral Immunity to *P. falciparum* Transmission-Blocking Candidate Pfs25 in Humans. Front Immunol. 2021;12:732667.
27. McGuire, K. A., K. Miura, C. M. Wiethoff and K. C. Williamson. New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit *Plasmodium falciparum* transmission. Malar J. 2017;16(1): 254.

28. Goodman, A. L., A. M. Blagborough, S. Biswas, Y. Wu, A. V. Hill, R. E. Sinden and S. J. Draper. A viral vectored prime-boost immunization regime targeting the malaria pfs25 antigen induces transmission-blocking activity. *PLoS One*. 2011; 6(12): e29428.
29. Diallo, M., A. M. Touré, S. F. Traoré, O. Niaré, L. Kassambara, A. Konaré, M. Coulibaly, M. Bagayogo, J. C. Beier, R. K. Sakai, Y. T. Touré and O. K. Doumbo. Evaluation and optimization of membrane feeding compared to direct feeding as an assay for infectivity. *Malar J*. 2008; 7(1): 248.
30. Miura, K., B. J. Swihart, B. Deng, L. Zhou, T. P. Pham, A. Diouf, T. Burton, M. P. Fay and C. A. Long. Transmission-blocking activity is determined by transmission-reducing activity and number of control oocysts in *Plasmodium falciparum* standard membrane-feeding assay. *Vaccine*. 2016;34(35): 4145-4151.
31. Miura, K., B. J. Swihart, M. P. Fay, C. Kumpitak, K. Kiattibutr, J. Sattabongkot and C. A. Long. Evaluation and modeling of direct membrane-feeding assay with *Plasmodium vivax* to support development of transmission blocking vaccines. *Sci Rep*. 2020;10(1): 12569.
32. Yusuf, Y., T. Yoshii, M. Iyori, H. Mizukami, S. Fukumoto, D. S. Yamamoto, T. B. Emran, F. Amelia, A. Islam, I. Syafira and S. Yoshida. A viral-vectored multi-stage malaria vaccine regimen with protective and transmission-blocking efficacies. *Front Imm*. 2019;10: 2412-2412.
33. Carter R, Mendis KN, Miller LH, Molineaux L, Saul A. Malaria transmission-blocking vaccines--how can their development be supported? *Nat Med*. 2000;6(3):241-4.
34. Yusuf, Y., T. Yoshii, M. Iyori, K. Yoshida, H. Mizukami, S. Fukumoto, D. S. Yamamoto, A. Alam, T. B. Emran, F. Amelia, A. Islam, H. Otsuka, E. Takashima, T. Tsuboi and S. Yoshida. Adeno-associated virus as an effective malaria booster vaccine following adenovirus priming. *Front Imm*. 2019;10: 730.
35. Alsulami MN. Eradication of Malaria: Present Situations and New Strategies. *J. Pharm. Res. Int.* [Internet]. 2021 Oct. 23 [cited 2024 Jun. 15];33(47A):17-3. Available from: <https://journaljpri.com/index.php/JPRI/article/view/3790>
36. Nassar A, Adedokun AA, Onosakponome EO, Adegun OJ, Bakare SA, Ayodele EA. The Efficacy of Bio-synthesized Silver Nanoparticles with Carica papaya Extract against Plasmodium berghei Infected Mice. *J. Adv. Med. Med. Res.* [Internet]. 2022 Dec. 5 [cited 2024 Jun. 15];34(23):482-95. Available from: <https://journaljammr.com/index.php/JAMMR/article/view/4885>
37. Li Y, Leneghan DB, Miura K, Nikolaeva D, Brian IJ, Dicks MD, Fyfe AJ, Zakutansky SE, de Cassan S, Long CA, Draper SJ. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology. *Scientific reports*. 2016 Jan 8;6(1):18848.
38. Menon V, Kapulu MC, Taylor I, Jewell K, Li Y, Hill F, Long CA, Miura K, Biswas S. Assessment of antibodies induced by multivalent transmission-blocking malaria vaccines. *Frontiers in immunology*. 2018 Jan 19;8:291049.